Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pemetrexed × Sarcoma × Clear all

Phase

Status

Completed 8 Unknown 1 Terminated 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 115 CNS 11 Other solid neoplasm 8 Gastrointestinal 6 Tumor-Agnostic 3 Gynecologic 3 Head & Neck 2 Genitourinary 2 Dermatologic 2 Breast 2 Sarcoma 1 Other 1

Conditions

Interventions

Doxorubicin 23 Cyclophosphamide 19 Specimen Handling 18 pembrolizumab 16 Temozolomide 14 Biopsy 14 Gemcitabine 13 Magnetic Resonance Spectroscopy 11 Blood Specimen Collection 11 fludarabine 10 atezolizumab 10 Surgical Procedures, Operative 10 Radiotherapy 10 Vincristine 8 Ifosfamide 8 Drug Therapy 8 Trabectedin 7 Nivolumab 7 Surveys and Questionnaires 6 Radiation 6 Imatinib Mesylate 6 cabozantinib 5 Standard of Care 5 Radiation Dose Hypofractionation 5 Irinotecan 5 Dactinomycin 5 selinexor 4 liposomal doxorubicin 4 irinotecan sucrosofate 4 fludarabine phosphate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06794645 2025-01-27

Pembrolizumab and Pemetrexed for Progressive Chordoma

Saint John's Cancer Institute

Phase 2 Recruiting

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡